Outlook Therapeutics Inc Live Stock Price Today, Share Analysis and Chart

Name: Outlook Therapeutics Inc: Is Infosys Ltd. worth buying?
Item: Outlook Therapeutics Inc
Rating: 0.81100
Author: Trendlyne DVM scores

about

Outlook Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an oph...

0.94 0.05 (5.62%)

88.70% Fall from 52W High

4.4M

XNAS Volume

XNAS 05 Sep, 2025 5:30 PM (EDT)

Not Eligible

Expensive Valuation

4.5 / 100

Technically Bearish

27.9 / 100

No estimates available

Outlook Therapeutics Inc Live Price Chart

Switch to TradingView

Loading Fundamental data..

Loading data..

Outlook Therapeutics Inc Live Stock Price Today, Share Analysis and Chart

Outlook Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an oph...

88.70% Fall from 52W High

SWOT Analysis

Outlook Therapeutics Inc Live Price Chart